Cargando…
EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma
PURPOSE: To assess expression levels of Ephrin type-A receptor 2 (EphA2), vascular endothelial growth factor (VEGF), and von Willebrand factor (vWF), and assess their potentials as prognostic biomarkers to predict the risk of poor survival in patients with primary lower grade glioma. METHOD: The stu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837893/ https://www.ncbi.nlm.nih.gov/pubmed/33545987 http://dx.doi.org/10.1097/MD.0000000000023985 |
_version_ | 1783643048075329536 |
---|---|
author | Shen, Likui Sun, Ran Kan, Shifeng Wang, Zhimin Yu, Zhengquan |
author_facet | Shen, Likui Sun, Ran Kan, Shifeng Wang, Zhimin Yu, Zhengquan |
author_sort | Shen, Likui |
collection | PubMed |
description | PURPOSE: To assess expression levels of Ephrin type-A receptor 2 (EphA2), vascular endothelial growth factor (VEGF), and von Willebrand factor (vWF), and assess their potentials as prognostic biomarkers to predict the risk of poor survival in patients with primary lower grade glioma. METHOD: The study included75 patients with histopathologically confirmed primary glioma (World Health Organization Grade IV). All patients underwent combined surgery and postoperative radiotherapy for the management of primary glioma. Immuno-histochemical analysis was performed to evaluate expression levels ofEphA2 and VEGF. Evaluation of tumor microvessel density was also performed at angiogenesis hot spots due to tumor growth. Main outcomes of the study were the prognostic efficiencies of EphA2, VEGF, and vWF in primary low-grade glioma, as well as whether their expression levels were associated with cancer progression. RESULTS: Of the patients with glioma, 67% had very strong expression of EphA2. Overall survival was inversely correlated with the expression of EphA2. Regarding VEGF expression, 38 patients (51%) had strong expression, 29 patients (39%) had weak expression, and 8 patients (11%) had no expression. Strong VEGF expression was associated with poor prognosis and poor survival. CONCLUSION: EphA2, VEGF, and vWF could be considered prognostic markers for assessment of primary glioma. |
format | Online Article Text |
id | pubmed-7837893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-78378932021-01-27 EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma Shen, Likui Sun, Ran Kan, Shifeng Wang, Zhimin Yu, Zhengquan Medicine (Baltimore) 5700 PURPOSE: To assess expression levels of Ephrin type-A receptor 2 (EphA2), vascular endothelial growth factor (VEGF), and von Willebrand factor (vWF), and assess their potentials as prognostic biomarkers to predict the risk of poor survival in patients with primary lower grade glioma. METHOD: The study included75 patients with histopathologically confirmed primary glioma (World Health Organization Grade IV). All patients underwent combined surgery and postoperative radiotherapy for the management of primary glioma. Immuno-histochemical analysis was performed to evaluate expression levels ofEphA2 and VEGF. Evaluation of tumor microvessel density was also performed at angiogenesis hot spots due to tumor growth. Main outcomes of the study were the prognostic efficiencies of EphA2, VEGF, and vWF in primary low-grade glioma, as well as whether their expression levels were associated with cancer progression. RESULTS: Of the patients with glioma, 67% had very strong expression of EphA2. Overall survival was inversely correlated with the expression of EphA2. Regarding VEGF expression, 38 patients (51%) had strong expression, 29 patients (39%) had weak expression, and 8 patients (11%) had no expression. Strong VEGF expression was associated with poor prognosis and poor survival. CONCLUSION: EphA2, VEGF, and vWF could be considered prognostic markers for assessment of primary glioma. Lippincott Williams & Wilkins 2021-01-22 /pmc/articles/PMC7837893/ /pubmed/33545987 http://dx.doi.org/10.1097/MD.0000000000023985 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 5700 Shen, Likui Sun, Ran Kan, Shifeng Wang, Zhimin Yu, Zhengquan EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma |
title | EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma |
title_full | EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma |
title_fullStr | EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma |
title_full_unstemmed | EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma |
title_short | EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma |
title_sort | epha2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837893/ https://www.ncbi.nlm.nih.gov/pubmed/33545987 http://dx.doi.org/10.1097/MD.0000000000023985 |
work_keys_str_mv | AT shenlikui epha2vascularendothelialgrowthfactorandvascularendothelialgrowthfactorcorrelatewithadverseoutcomesandpoorsurvivalinpatientswithglioma AT sunran epha2vascularendothelialgrowthfactorandvascularendothelialgrowthfactorcorrelatewithadverseoutcomesandpoorsurvivalinpatientswithglioma AT kanshifeng epha2vascularendothelialgrowthfactorandvascularendothelialgrowthfactorcorrelatewithadverseoutcomesandpoorsurvivalinpatientswithglioma AT wangzhimin epha2vascularendothelialgrowthfactorandvascularendothelialgrowthfactorcorrelatewithadverseoutcomesandpoorsurvivalinpatientswithglioma AT yuzhengquan epha2vascularendothelialgrowthfactorandvascularendothelialgrowthfactorcorrelatewithadverseoutcomesandpoorsurvivalinpatientswithglioma |